Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8131 to 8145 of 8904 results

  1. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  2. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

    Withdrawn advice

  3. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice

  4. Fatigue in multiple sclerosis: modafinil (ESUOM9)

    This advice has been updated and replaced by NICE guideline NG220.

    Withdrawn advice

  5. GaitSmart assessment and vGym personalised exercise rehabilitation programme for people with gait and mobility issues (MIB283)

    This medtech innovation briefing has been replaced by NICE healthtech guidance 716.

    Withdrawn advice

  6. AposHealth for knee osteoarthritis (MIB284)

    This medtech innovation briefing has been updated and replaced by NICE healthtech guidance 671. 

    Withdrawn advice

  7. Genedrive MT-RNR1 ID System for detecting single nucleotide polymorphism m.1555A G in newborn babies (MIB290)

    This medtech innovation briefing has been updated and replaced by NICE's early value assessment guidance on Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.

    Withdrawn advice

  8. Artificial intelligence for analysing chest X-ray images (MIB292)

    This medtech innovation briefing has been updated and replaced by HealthTech guidance 696. 

    Withdrawn advice

  9. Kurin Lock for blood culture collection (MIB297)

    This medtech innovation briefing (MIB) has been replaced by NICE healthtech guidance 715.

    Withdrawn advice

  10. Prontosan for acute and chronic wounds (MIB220)

    This advice has been updated and replaced by NICE healthtech guidance 616.

    Withdrawn advice

  11. Synergo for non-muscle-invasive bladder cancer (MIB226)

    This advice has been updated and replaced by NICE healthtech guidance 601.

    Withdrawn advice

  12. AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229)

    This advice has been updated and replaced by NICE healthtech guidance 607.

    Withdrawn advice

  13. TriageHF Plus for remotely monitoring people with cardiac implantable electronic devices at risk of heart failure or worsening heart failure (MIB298)

    This advice has been updated and replaced by NICE healthtech guidance 730.

    Withdrawn advice

  14. Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease (MIB300)

    This advice has been updated and replaced by NICE healthtech guidance 736.

    Withdrawn advice

  15. The Prosigna gene expression profiling assay for assessing long‑term risk of breast cancer recurrence (MIB27)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

    Withdrawn advice